Archive · 22 Jul 2026
India Approves First Dengue Vaccine
India has approved its first dengue vaccine called QDENGA.
This vaccine is made by Takeda Biopharmaceuticals India and is meant to prevent dengue in people aged 4 to 60 years.
The vaccine has been tested in many countries and has been approved in 42 countries, including some in Europe and Asia.
It is given in two doses, three months apart.
The government says this is a big step in fighting dengue in India.
Some people are happy about the vaccine, but others have concerns about its safety and the use of genetically modified organisms.
India has approved its first dengue vaccine, QDENGA, manufactured by Takeda Biopharmaceuticals India.
The vaccine is approved for individuals aged 4 to 60 years and is administered in two doses.
QDENGA has been approved in 42 countries and has received WHO prequalification.
The vaccine has undergone extensive clinical trials and has a favorable safety profile.
The approval is expected to complement ongoing efforts to control dengue in India.
- Who
- The government of India and Takeda Biopharmaceuticals India Pvt Ltd
- What
- Approval of the first dengue vaccine, QDENGA
- When
- Tuesday (specific date not mentioned)
- Where
- India
- Why
- To prevent dengue disease in individuals aged 4 to 60 years
Pro-Vaccination Advocates
Vaccine Skeptics
Vaccine Safety and Efficacy
Pro-Vaccination Advocates
The vaccine has undergone rigorous clinical trials and has been approved in 42 countries, demonstrating its safety and efficacy.
Vaccine Skeptics
Some skeptics question the long-term effects and the use of genetically modified organisms in the vaccine.
- Vaccine Name
- QDENGA
- Manufacturer
- Takeda Biopharmaceuticals India Pvt Ltd
- Approval Date
- Tuesday (specific date not mentioned)
- Target Age Group
- 4 to 60 years
- Immunisation Schedule
- Two doses of 0.5 ml each, administered at an interval of three months
- Global Approvals
- 42 countries, including the European Union, the United Kingdom, Switzerland, Indonesia, Malaysia, and Thailand
- WHO Prequalification
- Yes
- Global Doses Distributed
- More than 24 million
